Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), wherein the dsRNA agent comprises a sense strand and an antisense strand, the antisense strand comprising at least 15 contiguous nucleotides of the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAUAU-3′ (SEQ ID NO: 126) or at least 15 contiguous nucleotides of the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAAAU-3′ (SEQ ID NO: 149),
wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides.
2. The dsRNA agent of claim 1 , wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a modification.
3. The dsRNA agent of claim 1 , wherein the modified nucleotides are selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, and a nucleotide comprising a 5′-phosphate mimic.
4. The dsRNA agent of claim 1 , further comprising at least one phosphorothioate internucleotide linkage.
5. The dsRNA agent of claim 1 , wherein each strand is independently 21 to 23 nucleotides in length; 21 nucleotides in length; 19 nucleotides in length; or at least 17 nucleotides in length.
6. The dsRNA agent of claim 1 , wherein each strand is no more than 30 nucleotides in length; each strand is independently 19-30 nucleotides in length; or each strand is independently 19-25 nucleotides in length.
7. The dsRNA agent of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide; or a 3′ overhang of at least 2 nucleotides.
8. The dsRNA agent of claim 1 , further comprising a ligand.
9. The dsRNA agent of claim 8 , wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.
10. The dsRNA agent of claim 9 , wherein the ligand is an N-acetylgalactosamine (GalNAc) derivative.
11. The dsRNA agent of claim 10 , wherein the ligand is
12. The dsRNA agent of claim 11 , wherein the dsRNA agent is conjugated to the ligand as shown in the following schematic
and, wherein X is O or S.
13. The dsRNA agent of claim 1 , wherein the dsRNA agent comprises an antisense strand comprising at least 19 contiguous nucleotides of the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAUAU-3′ (SEQ ID NO: 126) or at least 19 contiguous nucleotides of the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAAAU-3′ (SEQ ID NO: 149).
14. The dsRNA agent of claim 1 , wherein the dsRNA agent comprises an antisense strand comprising the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAUAU-3′ (SEQ ID NO: 126).
15. The dsRNA agent of claim 1 , wherein the dsRNA agent comprises an antisense strand comprising the nucleotide sequence of 5′-AAUAUUUACCUUUUGUAGAAAAU-3′ (SEQ ID NO: 149).
16. The dsRNA agent of claim 1 , wherein the dsRNA agent comprises a sense strand comprising at least 15 contiguous nucleotides of the nucleotide sequence of 5′-AUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 39) or 5′-UUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 62).
17. The dsRNA agent of claim 1 , wherein the dsRNA agent comprises a sense strand comprising at least 19 contiguous nucleotides of the nucleotide sequence of 5′-AUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 39) or 5′-UUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 62).
18. The dsRNA agent of claim 1 , wherein the sense strand and the antisense strand comprise nucleotide sequences selected from the group consisting of:
(a) 5′-AUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 39) and 5′-AAUAUUUACCUUUUGUAGAAUAU-3′ (SEQ ID NO: 126);
(b) 5′-UUUCUACAAAAGGUAAAUAUU-3′ (SEQ ID NO: 62) and 5′-AAUAUUUACCUUUUGUAGAAAAU-3′ (SEQ ID NO: 149);
(c) 5′-AfsusUfcUfaCfaAfAfAfgGfuAfaAfuAfuUfL96-3′ (SEQ ID NO: 213) and 5′-asAfsuAfuUfuAfcCfuuuUfgUfaGfaAfusasu-3′ (SEQ ID NO: 300); and
(d) 5′-UfsusUfcUfaCfaAfAfAfgGfuAfaAfuAfuUfL96-3′ (SEQ ID NO: 236) and 5′-asAfsuAfuUfuAfcCfuuuUfgUfaGfaAfasasu-3′ (SEQ ID NO: 323),
wherein a is 2′-O-methyladenosine-3′-phosphate, c is 2′-O-methylcytidine-3′-phosphate, g is 2′-O-methylguanosine-3′-phosphate, u is 2′-O-methyluridine-3′-phosphate; Af is 2′-fluoroadenosine-3′-phosphate, Cf is 2′-fluorocytidine-3′-phosphate, Gf is 2′-fluoroguanosine-3′-phosphate, Uf is 2′-fluorouridine-3′-phosphate, s is a phosphorothioate linkage, and L96 is N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol.
19. A pharmaceutical composition for inhibiting expression of a KLKB1 gene, comprising the dsRNA agent of claim 1 .
20. A method of inhibiting expression of a KLKB1 gene in a cell, the method comprising:
(a) contacting the cell with the dsRNA agent of claim 1 , or a pharmaceutical composition of claim 19 ; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of the contact activation pathway gene, thereby inhibiting expression of the contact activation pathway gene in the cell.
21. The method of claim 20 , wherein said cell is within a subject.
22. The method of claim 21 , wherein the subject is a human.
23. A method of treating a subject having a disease or disorder that would benefit from reduction in expression of a contact activation pathway gene, the method comprising administering to the subject a therapeutically effective amount of the dsRNA agent of claim 1 , or a pharmaceutical composition of claim 19 , thereby treating said subject.